On Wednesday, Following Stocks were among the “Top Gainers” of U.S. Stock Market: Agnico Eagle Mines, (NYSE:AEM), Approach Resources, (NASDAQ:AREX), Hercules Offshore, (NASDAQ:HERO), Sarepta Therapeutics, (NASDAQ:SRPT)
Agnico Eagle Mines, (NYSE:AEM), with shares gained 8.05%, closed at $30.19.
Approach Resources, (NASDAQ:AREX), with shares jumped 8.04%, settled at $7.12.
Hercules Offshore, (NASDAQ:HERO), with shares climbed 8.02%, and closed at $0.45.
Sarepta Therapeutics, (NASDAQ:SRPT), gained 7.61%, and closed at $14.29.
Latest NEWS regarding these Stocks are depicted underneath:
Agnico Eagle Mines Limited (NYSE:AEM)
Agnico Eagle Mines Limited (AEM), declared that it has made several senior administration appointments and that it will release its first quarter 2015 results on Thursday, April 30, 2015 , after normal trading hours. Additionally, the Corporation will host its Annual General Meeting the following day, Friday, May 1, 2015 , in Toronto .
Agnico Eagle’s senior administration will host a conference call on Friday, May 1, 2015 at 8:30 AM (E.D.T.) to talk about the corporation’s financial and operating results.
Agnico Eagle Mines Limited engages in the exploration, development, and production of mineral properties. It primarily explores for gold, in addition to for silver, copper, zinc, and lead. The Corporation and its shareholders have full exposure to gold prices due to its long-standing policy of no forward gold sales. Agnico Eagle has declared a cash dividend every year since 1983.
Approach Resources, Inc. (NASDAQ:AREX)
Approach Resources, Inc. (AREX), has price to sale ratio of 1.12, however, price to book ratio is 0.36. With recent incline, the year-to-date (YTD) performance reflected a 11.42% incline. During the past month the stocks lose -11.77%, bringing three-month performance to 11.77% and six-month performance to -50.90%. The mean recommendation of analysts for this stock is 3.10. (where 1=Buy, 5=Sale).
Approach Resources Inc., an independent energy corporation, focuses on the exploration, development, production, and attainment of unconventional oil and gas reserves in the United States.
Hercules Offshore, Inc. (NASDAQ:HERO)
Formerly on March 23, Hercules Offshore, Inc. (HERO), declared that it has published the March Fleet Status Report. The Report comprises the Hercules Offshore Rig Fleet Status (as of March 23, 2015), which contains detailed contract information for each of the Corporation’s drilling rigs. The Report also comprises the Hercules Offshore Liftboat Fleet Status Report, which contains information by liftboat class for February 2015, counting proceed per day and operating days.
Hercules Offshore, Inc., together with its auxiliaries, provides shallow-water drilling and marine services to the oil and natural gas exploration and production industry worldwide. The corporation operates through Domestic Offshore, International Offshore, and International Liftboats segments.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Sarepta Therapeutics, Inc. (SRPT), declared the appointment of Edward Kaye, M.D., the corporation’s Chief Medical Officer (CMO), as interim Chief Executive Officer (CEO) effective right away. He replaces Christopher Garabedian, who resigned as President and Chief Executive Officer and as a member of the Board, also effective right away. Dr. Kaye, who will continue in a dual capacity as CEO and CMO while the corporation conducts a search for a new full-time CEO, will focus his efforts on heading the regulatory and clinical process for the corporation’s lead product candidate, eteplirsen, and follow on “exon” drug candidates for Duchenne Muscular Dystrophy (DMD).
Dr. Kaye is a Neurological Consultant at the Children’s Hospital of Boston and is on the editorial boards of a number of journals, counting the Journal of Child Neurology. He is also on the Medical/Scientific Advisory Boards of the United Leukodystrophy Foundation, Spinal Muscular Atrophy Foundation, CureCMD, CureDuchenne and the Prize4Life.
Sarepta Therapeutics, Inc., a biopharmaceutical corporation, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. Its lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development stage for the treatment of individuals with Duchenne muscular dystrophy (DMD), a rare genetic muscle-wasting disease caused by the absence of dystrophin.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
